Bicara Therapeutics (BCAX) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MeiraGTx (MGTX) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 27.4% versus a loss of 9.6%. Bicara Therapeutics is the larger company by market cap ($1.09 billion vs $1.04 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | MGTX |
|---|---|---|
| Share price | $16.42 | $10.82 |
| Market cap | $1.09B | $1.04B |
| 1-day change | -0.85% | +2.08% |
| YTD return | -2.44% | +36.10% |
| 1-year return | -9.63% | +27.44% |
| 5-year return | — | -24.23% |
| P/E ratio (TTM) | — | 12.44 |
| EPS (TTM) | $-3.08 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $15.35 |
| 52-week low | $13.70 | $6.62 |
| Distance from 52-week high | -47.02% | -29.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.20% | +156.47% |
| Average volume | 610.46K | 797.37K |
| Shares outstanding | 66.17M | 96.04M |
| Employees | 103 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed BCAX by 37.1 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
BCAX vs MGTX FAQ
Which is bigger, Bicara Therapeutics or MeiraGTx?
Bicara Therapeutics (BCAX) is larger, with a market capitalization of $1.09B compared with $1.04B for MeiraGTx (MGTX).
Which stock has performed better over the past year, BCAX or MGTX?
MGTX returned +27.44% over the past 12 months, compared with -9.63% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and MeiraGTx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Bicara Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for MeiraGTx.